Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 5Glioblastoma 4Oligodendroglioma 3Gliosarcoma 3Glioma 3Brain Neoplasms 3Astrocytoma 3Prostatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Supratentorial Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Optic Nerve Glioma 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 71apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × lonafarnib × Clear all
NCT00539968 2015-02-05

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
5 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡